Given the favorable biodistribution profile of ELP-fused VEGF or PlGF and a careful dosing strategy to achieve proper VEGF or PlGF replacement, we believe that this approach represents a promising new method for preeclampsia therapy. This evidence concerns the gene PGF and preeclampsia.